Eiger BioPharmaceuticals Inc

NASDAQ:EIGR   3:59:54 PM EDT
8.75
-0.29 (-3.21%)
Products

FDA Approves First Treatment For Hutchinson-Gilford Progeria Syndrome And Some Progeroid Laminopathies

Published: 11/20/2020 23:33 GMT
Eiger BioPharmaceuticals Inc (EIGR) - FDA Approves First Treatment for Hutchinson-gilford Progeria Syndrome and Some Progeroid Laminopathies.
FDA - Zokinvy is Not Approved for Use in Patients With Other Progeroid Syndromes Or Laminopathies.
FDA - Granted Approval of Zokinvy to Eiger Biopharmaceuticals, Inc.